Related Experiment Video
Updated: May 9, 2025
08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.3K
A Multimodal Therapeutic Strategy for Inflammatory Bowel Disease Using MicroRNA-146a Mimic Encapsulated in Lipid
Kanika Suri1,2, Vishnu Hosur3, Rohit Panchakshari1
1Takeda Development Center Americas, Cambridge, Massachusetts 02142, United States.
Molecular Pharmaceutics
|May 5, 2025
Summary
MicroRNAs (miRNAs) show therapeutic potential for inflammatory bowel disease (IBD). Lipid nanoparticle delivery of miRNA-146a effectively reduced inflammation in IBD models, suggesting a promising treatment strategy.
Area of Science:
- Molecular biology
- Immunology
- Gastroenterology
Background:
- Dysregulated microRNAs (miRNAs) are implicated in chronic diseases, with therapeutic potential yet to be fully realized.
- miRNAs regulate multiple pathways, making them candidates for treating complex diseases like inflammatory bowel disease (IBD).
- miRNA-146a exhibits anti-inflammatory properties and is relevant to IBD pathogenesis.
Purpose of the Study:
- To review literature on miRNA-146 levels in IBD.
- To investigate the role of miRNA-146a in IBD.
- To evaluate lipid nanoparticle (LNP)-mediated delivery of miRNA-146a to macrophages for IBD treatment.
Main Methods:
- Literature review of miRNA-146 in IBD patients and models.
- Quantification of miRNA-146a and miRNA-146b expression in a dextran sodium sulfate (DSS)-induced mouse colitis model.
- Investigation of LNP-based delivery of miRNA-146a to macrophages in an inflammation model.
Main Results:
- miRNA-146a expression was upregulated in the DSS-induced IBD mouse model.
- LNP-mediated delivery of miRNA-146a successfully downregulated inflammatory genes.
- Macrophages were identified as key targets for miRNA-146a delivery.
Conclusions:
- miRNA-146a plays a critical role in modulating inflammation in IBD.
- LNP-based delivery of miRNA-146a represents a potential therapeutic strategy for IBD.
- Targeted delivery of miRNAs offers a novel approach for managing inflammatory diseases.
More Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
79
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
98
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
98
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
97
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
97
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
84
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
84
01:29Drugs for Treatment of Ulcerative Colitis in IBD
101
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
101
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
219
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
219